UMass Chan Medical School

What UMass Chan Medical School does

UMass Chan Medical School is the Commonwealth of Massachusetts's first and only public academic health sciences center, established by legislation in 1962 and headquartered in Worcester on a campus that anchors the region's academic medicine ecosystem. The institution comprises three graduate schools — the T.H. Chan School of Medicine (ranked #1 in Massachusetts for primary care education for over 30 years per U.S. News & World Report), the Morningside Graduate School of Biomedical Sciences, and the Tan Chingfen Graduate School of Nursing — that together educate approximately 1,400 students and graduate 175 medical students per cohort. The research enterprise is anchored by the discoveries of two Nobel Laureates housed on the same faculty: Craig C. Mello (2006, RNA interference) and Victor R. Ambros (2024, microRNA), whose work underpins the RNA Therapeutics Institute and the institution's leadership in RNA biology, gene therapy, and cancer biology.

The underlying scientific and operational platform spans basic biomedical discovery, translational research, clinical trials (500+ active), and downstream biomanufacturing. MassBiologics — the only nonprofit FDA-licensed manufacturer of vaccines, biologics, and viral vector gene therapies in the United States, with cGMP facilities in Boston and Fall River — provides commercial-grade biomanufacturing capacity that produced licensed products including Zinplava (bezlotoxumab, with Merck) and Rabishield (with the Serum Institute of India). Research infrastructure is reinforced by the Albert Sherman Center (500,000 sq ft), the Ambulatory Care Center, and 20+ research core facilities, with FY2025 research funding of approximately $305 million across 345 NIH awards and additional private and state sources.

The business model is multi-revenue-stream and reflects a hybrid academic/commercial structure. Federal research grants (primarily NIH at $190.4M in FY2025) constitute the largest single revenue category; tuition from medical, nursing, and graduate programs provides a stable subscription base; MassBiologics generates CMO services revenue from biopharma clients (SparingVision, PTC Therapeutics, gene therapy developers); ForHealth Consulting delivers healthcare consulting to public-sector clients; and licensing/royalty income flows through BRIDGE Innovation and Business Development from deals such as the Tonix Pharmaceuticals TNX-4800 Lyme PrEP license (2025) and the Etienna Bio adipose-derived regenerative platform license (2026). Philanthropy is material, anchored by The Morningside Foundation's $175 million unrestricted gift (2021) — which triggered the institution's renaming — and a $35 million gift from the Paul J. DiMare Foundation (2025) supporting neurodegenerative and genetic disease research as part of the $500 million Advancing Together comprehensive campaign.

Name

UMass Chan Medical School

Legal name

UMass Chan Medical School

Website

https://umassmed.edu

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

UMass Chan Medical School is Massachusetts's public academic health sciences center, operating three graduate schools (medicine, biomedical sciences, nursing) plus MassBiologics, the only nonprofit FDA-licensed vaccine and biologics manufacturer in the United States.

Ownership category

akta.pro rank

Product category

Academic Medical Center / Medical Education

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Offices of Physicians (except Mental Health Specialists) (621111), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Health Services (8000), Biological Products, (No Disgnostic Substances) (2836), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC), Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC)

Keywords

• Medical education
• Biomedical research
• Biologics manufacturing
• Healthcare consulting
• Clinical trials

Headquarters

HQ city

Worcester

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Federal Research Grants: NIH and other federal grants for biomedical research, approximately $305 million in FY2025. NIH awards totaled $190.4 million from 345 awards in fiscal 2025.
2. Private Foundation & Corporate Research Funding: Funding from private foundations, corporations, and organizations for specific research programs and fellowships.
3. MassBiologics Manufacturing Services: Contract manufacturing services for vaccines, biologics, and gene therapies through MassBiologics CMO services including development, cGMP manufacturing, and quality services.
4. ForHealth Consulting: Public service health care consulting division providing operations and consulting services to healthcare organizations.
5. Tuition & Educational Programs: Revenue from medical, nursing, and graduate school education programs across three schools.
6. Licensing & Technology Transfer: Revenue from licensing technologies including the TNX-4800 Lyme disease antibody (to Tonix Pharmaceuticals), adipose-derived regenerative platform (to Etienna Bio), and Tau antibody portfolio.
7. State Funding (DRIVE Initiative): Proposed $400 million Massachusetts DRIVE initiative to support research offsetting federal funding gaps.
8. Philanthropic Donations: Major gifts including $175 million from Morningside Foundation, $35 million from Paul J. DiMare Foundation, and ongoing fundraising campaign (Advancing Together - $500 million goal).

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

UMass Chan Medical School is a public academic health sciences center that delivers graduate-level medical, biomedical, and nursing education across three schools, conducts federally funded biomedical research, and operates two commercial service divisions. MassBiologics provides FDA-licensed contract manufacturing of vaccines, biologics, and gene therapies, while ForHealth Consulting delivers healthcare consulting to public-sector clients. The institution also licenses proprietary technologies (including Lyme PrEP antibodies, Tau diagnostics, and regenerative cell platforms) to industry partners.

Product overview

UMass Chan Medical School is a public academic health sciences center comprising three graduate schools (T.H. Chan School of Medicine, Morningside Graduate School of Biomedical Sciences, and Tan Chingfen Graduate School of Nursing) plus two business divisions (MassBiologics and ForHealth Consulting). The institution offers medical education (MD, MD/PhD, MD/MBA), graduate biomedical sciences education (PhD, MS), and nursing education (MS, DNP, PhD). Research infrastructure includes the RNA Therapeutics Institute, Gene Therapy Center, and 20+ research core facilities. MassBiologics is the only nonprofit FDA-licensed manufacturer of vaccines and biologics in the U.S. Clinical trials are managed through the Conquering Diseases platform. The institution has produced two Nobel laureates and receives approximately $305 million in annual research funding.

Differentiator

Problem solved

Functional benefit

Brands

• T.H. Chan School of Medicine: One of the three graduate schools of UMass Chan Medical School, committed to training in the full range of medical disciplines with emphasis on primary care specialties and underserved areas
• Tan Chingfen Graduate School of Nursing
• Morningside Graduate School of Biomedical Sciences
• MassBiologics
• ForHealth Consulting

Products and services

• T.H. Chan School of Medicine Medical school offering MD, MD/PhD, and MD/MBA programs, ranked #1 in Massachusetts for primary care education for over 30 years. Committed to training physicians in full range of medical disciplines with emphasis on primary care specialties and underserved areas.
• Morningside Graduate School of Biomedical Sciences Graduate school offering PhD, MD/PhD, and Master of Science in Clinical Investigation programs in basic biomedical sciences with relevance to human disease. Ranked 55th among 159 doctoral programs in biological sciences with $1.5 billion in NIH funding over the past decade.
• Tan Chingfen Graduate School of Nursing Graduate nursing school offering Master's, Doctor of Nursing Practice (DNP), and PhD programs preparing nurses for advanced practice and leadership roles. Ranked 29th of 154 DNP programs nationally with 100% FNP pass rate and guaranteed clinical placements.
• MassBiologics Contract Manufacturing Organization The only nonprofit FDA-licensed manufacturer of vaccines, biologics, and viral vector gene therapies in the United States. Provides development, cGMP manufacturing, and quality services including non-GMP monoclonal antibody production, cell line development, aseptic fill-finish, and analytical method development for biopharmaceutical clients.
• ForHealth Consulting Public service consulting and operations division of UMass Chan Medical School providing health care consulting services to healthcare organizations, government agencies, and public-sector clients on healthcare delivery, policy, and operations.
• Conquering Diseases Clinical Trials Platform Web-based clinical trials management and patient-recruitment tool that allows patients to find, share, and save clinical studies. Supports enrollment for trials spanning cancer, ALS, stroke, muscular dystrophy, autoimmune conditions, and other diseases.

Quantifiable outcome

• 42% of medical students enter primary care specialties
• +4 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

Partnerships

15 partnerships are on record, tiered major and core.

• NanoDetection TechnologymajorTechnology or Integration · 12 June 2026Exclusive worldwide licensing agreement for portfolio of nine specialized Tau antibodies for advancing diagnostics for Alzheimer's disease and related neurodegenerative disorders. Technology enables detection of specific forms of aggregated Tau distinguishing Alzheimer's from Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. Integrated into NanoDetection's TRACE-Tau platform with clinical validation ongoing.
• Community ServingscoreStrategic or Co-development Partner · 2 June 2026Partnership for medically tailored meals research study published in Nature Medicine showing 31% reduction in hospitalizations and $3,433 lower healthcare costs per patient for Massachusetts Medicaid patients.
• Harvard Pilgrim Health Care InstitutecoreStrategic or Co-development Partner · 18 May 2026Collaborative research on children's mental health needs analyzing insurance claims data for 1.8 million insured children in Massachusetts, finding 300% surge in anxiety disorders.
• Boston UniversitycoreStrategic or Co-development Partner · 18 May 2026Collaborative research on pediatric mental health trends over nearly a decade, identifying primary care as critical frontline for detection.
• Boston Medical CentercoreStrategic or Co-development Partner · 18 May 2026Research collaboration on children's mental health needs, contributing to JAMA Network Open study on insurance claims data.
• Brown UniversitycoreStrategic or Co-development Partner · 18 May 2026Multi-institutional research partnership analyzing pediatric mental health trends, participating in study published in JAMA Network Open.
• Trenchant BioSystemsmajorStrategic or Co-development Partner · 31 March 2026Partnership to develop automated manufacturing platform for gene-modified hematopoietic stem cell therapies targeting sickle cell disease and beta thalassemia. Leverages Trenchant BioSystems' AutoCell platform using microbubble separation technology to reduce footprint and costs compared to conventional methods. Plans FDA INTERACT meeting Q1 2027 and Phase I/II clinical trial later that year.
• Caring CrossmajorStrategic or Co-development Partner · 31 March 2026Collaboration with Trenchant BioSystems and UMass Chan to develop automated manufacturing platform for gene-modified hematopoietic stem cell therapies. Aims to make cell and gene therapies more accessible and affordable for patients with sickle cell disease and beta thalassemia.
• SparingVisioncoreTechnology or Integration · 31 March 2026Partnership to manufacture gene therapy for ocular disease. MassBiologics provides development and manufacturing services for advanced therapies targeting inherited retinal diseases.
• Etienna BiomajorTechnology or Integration · 6 February 2026Exclusive worldwide license agreement for proprietary adipose-derived cellular and matrix technology platform combining autologous adipose-derived progenitor cells with hydrogel matrix for non-therapeutic regenerative and aesthetic applications. Platform offers biological compatibility, durability, and scalability while avoiding regulatory complexity of gene-modified approaches.
• Tonix PharmaceuticalsmajorTechnology or Integration · 1 January 2025UMass Chan licensed TNX-4800, a long-acting monoclonal antibody targeting Borrelia burgdorferi for Lyme disease prevention, to Tonix Pharmaceuticals in 2025. Phase 1 data showed single-dose injection was safe and well-tolerated with protective blood levels lasting approximately four months. Phase 2 field study planned for first half of 2027 pending FDA clearance.
• Lahey Hospital & Medical Center (Beth Israel Lahey Health)coreStrategic or Co-development Partner · 1 January 2023UMass Chan-Lahey regional campus partnership established 2023, providing medical education opportunities at Lahey Hospital & Medical Center in Burlington, part of Beth Israel Lahey Health system.
• PTC TherapeuticscoreTechnology or Integration · 1 August 2022Manufacturing partnership for gene therapy for rare pediatric condition. European Commission granted marketing authorization for Upstaza (eladocagene exuparvovec) for AADC deficiency, developed with PTC Therapeutics and manufactured at MassBiologics.
• Serum Institute of IndiacoreTechnology or Integration · 1 October 2017Partnership to develop and manufacture Rabishield, a rabies biological product. Serum Institute launched Rabishield, developed in partnership with MassBiologics, providing affordable rabies treatment globally.
• Baystate HealthcoreStrategic or Co-development Partner · 1 January 2015UMass Chan-Baystate regional campus partnership established 2015, expanding medical education to Springfield area with clinical training at Baystate Health facilities.

Scale indicators22 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Boston University Chobanian & Avedisian School of Medicine: Urban New England medical school with significant NIH-funded biomedical research and comparable urban primary care training footprint; competes directly with UMass Chan for students, faculty, and research funding in the Boston-Worcester corridor.
• Tufts University School of Medicine: New England-based medical and graduate biomedical sciences school with overlapping research strengths in infectious disease, neuroscience, and public health; competes for the same applicant pool and federal research dollars.
• University of Vermont Larner College of Medicine: Public medical school in New England with a comparable mix of medical education, biomedical PhD programs, and NIH-funded research; the closest analogue in public-mission positioning.
• University of Connecticut School of Medicine: Public New England medical school with combined MD and biomedical PhD programs that competes with UMass Chan for state research investment, NIH funding, and primary care workforce placement.
• Dartmouth Geisel School of Medicine: New England medical school with strong biomedical research portfolio and primary care emphasis; competes for the same regional applicant and faculty talent.
• Brown University Warren Alpert Medical School: Ivy League New England medical school with combined MD/PhD programs and primary care orientation; overlaps with UMass Chan on applicant profiles and biomedical research areas.

Broad incumbents

• Harvard Medical School: Premier Boston-based medical school with vastly larger research portfolio and endowment; competes for top faculty and trainees and sets the benchmark for NIH funding success in the region.
• Yale School of Medicine: Top-tier research medical school with substantially larger NIH funding base; a relevant benchmark for UMass Chan's RNA biology, genetics, and biomedical research ambitions.

Emerging players

• The Jackson Laboratory: Independent nonprofit biomedical research institute with deep expertise in genetics and mouse models; an emerging player in research services and training that overlaps with UMass Chan's biomedical sciences programs.
• Cold Spring Harbor Laboratory: Privately funded nonprofit research and educational institution focused on cancer biology, neuroscience, and quantitative biology; comparable in mission mix of biomedical research and graduate training.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/umasschan
• YouTubeyoutube.com/c/UMassChanMedicalSchool
• Facebookfacebook.com/umasschan
• LinkedInlinkedin.com/company/umasschan
• Instagraminstagram.com/umasschan

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UMass Chan Medical School